



Performance of Two Novel Obesity Indicators for the Management of Metabolic Syndrome in Young Adults

Xiaoli Liu¹, Chunpeng Ma^{2*}, Fuzai Yin¹, Rui Wang¹, Qiang Lu¹, Na Lu¹ and Chunming Ma¹

¹ Department of Endocrinology, The First Hospital of Qinhuangdao, Qinhuangdao, China, ² Department of Cardiology, The First Hospital of Qinhuangdao, Qinhuangdao, China

Background: Metabolic syndrome (MetS) is a pathophysiological change based on the abnormal metabolism of many substances. The study aims to investigate the performance of visceral adiposity index (VAI) and lipid accumulation product (LAP) of MetS in young adults.

Methods: 448 young adults aged between 19 and 24 years old in Qinhuangdao had been included in this cross-sectional study. Receiver operating characteristic (ROC) curve analyses were used to assess the accuracy of these two obesity indicators for MetS.

OPEN ACCESS

Edited by:

Claire Joanne Stocker, Aston University, United Kingdom

Reviewed by:

Aleksandra Klisic, Primary Health Care Center Podgorica, Montenegro Jose Ramon Alvero Cruz, Universidad de Málaga, Spain Mustafa Suat Bolat, Samsun Gazi State Hospital, Turkey

*Correspondence:

Chunpeng Ma mcpcom_123@163.com

Specialty section:

This article was submitted to Obesity, a section of the journal Frontiers in Endocrinology

Received: 02 June 2021 Accepted: 05 July 2021 Published: 26 July 2021

Citation:

Liu X, Ma C, Yin F, Wang R, Lu Q, Lu N and Ma C (2021) Performance of Two Novel Obesity Indicators for the Management of Metabolic Syndrome in Young Adults. Front. Endocrinol. 12:719416. doi: 10.3389/fendo.2021.719416 **Results:** The prevalence of MetS was 2.0%. In male subjects, LAP had the highest area under the ROC curve (AUC) value (AUC = 0.963), followed by VAI (AUC = 0.937). In female subjects, LAP also had the highest AUC value (AUC = 0.931), followed by VAI (AUC = 0.861). No significant difference was found between the two obesity indicators (P > 0.05).

Conclusion: The two obesity indicators were valuable for the screening of MetS in young adults, and LAP was the simpler of the two.

Keywords: visceral adiposity index, lipid accumulation product, metabolic syndrome, young adults, crosssectional study

INTRODUCTION

Metabolic syndrome (MetS) is a pathophysiological change based on the abnormal metabolism of many substances. It has many risk factors related to atherosclerosis, which eventually leads to the occurrence and development of cardiovascular and cerebrovascular diseases.

The early intervention of MetS is important for reducing the risk of developing related diseases. The VAI and LAP are two novel indexes for MetS. VAI and LAP are associated with many chronic diseases. VAI was negatively correlated with insulin sensitivity (1), and was identified as a powerful indicator of prediabetes or diabetes (2). It was positively correlated with the risk of hyperuricemia and nonalcoholic fatty liver disease (3, 4). VAI can predict the incidence of hypertension in prehypertension or healthy people (5). The VAI can be used as a reliable independent risk factor marker for Sexual Dysfunction (ED) as a predictor of visceral adipose dysfunction, and the presence of MeTS has emerged as a risk factor for patients with ED with high VAI levels (6, 7).

Recently, several studies have supported the use of these indexes for the screening of MetS in the healthy population (8–11), the elderly (12, 13), people with polycystic ovary syndrome (14–16) and those with adult growth hormone deficiency (17). The aim of our study was to evaluate the performance of two obesity indicators, VAI and LAP, for identifying MetS in young adults.

1

METHODS

Subjects

This is a cross-sectional, population-based study. The participants of this study were patients with metabolic syndrome who came to our hospital from May 18th, 2018. A total of 448 young adults of Han ethnicity, aged between 19 and 24 years old (males/females 235/213), participated in the study. Participants in this study were included in a consecutive manner. The exclusion criteria included the following: 1) patients with other endocrinopathy, such as Cushing's syndrome and hyperthyroidism; 2) subjects who were taking medication which affect lipid metabolism, such as glucocorticoids and fibrates; 3) subjects with acute and chronic inflammation. This study was approved by the ethics committee of the First Hospital of Qinhuangdao and all subjects had provided written informed consent before the study began.

Measurements

Anthropometric measurements included height, weight, waist circumference (WC) and Body mass index (BMI). Blood samples were collected after a 10-hour overnight fast. Fasting plasma glucose (FPG) concentration and serum lipid levels were measured.

VAI was calculated as follows (18): male subjects: VAI = $(WC/(39.68 + (1.88 \times BMI)) \times (TG/1.03) \times (1.31/HDL);$ female subjects: VAI = $(WC/(36.58 + (1.89 \times BMI)) \times (TG/0.81) \times (1.52/HDL)$. LAP was calculated as $(WC- 65) \times TG$ for men and $(WC- 58) \times TG$ for women (19).

Definition of Metabolic Syndrome

Participants had to meet three or more of the following five factors: 1) WC \geq 102 cm (male) and 88 cm (female), 2) FPG \geq 5.6 mmol/L or had been diagnosed with diabetes, 3) blood pressure \geq 130/85 mmHg or had been diagnosed with hypertension, 4) TG \geq 1.7 mmol/L, 5) HDL-C < 1.0 mmol/L (male) and 1.3 cm (female) (20).

Statistical Analyses

SPSS 11.5 (SPSS 11.5 for Windows; SPSS, Inc., Chicago, IL) was used for data analysis. Continuous variables were expressed as mean \pm standard deviation and comparisons between groups was conducted by *t*-test. Kolmogorov Smirnov (KS) test was used to

determine the type of data distribution. Comparison prevalence data was performed by χ^2 analysis. ROC curves were used to show how well they could separate subjects into groups with or without MetS. A test with an area under the curve (AUC) of ≥ 0.85 was considered accurate (21). The sensitivity and specificity of each obesity indicator was calculated at all possible cut-off points to find the optimal cut-off values. The optimal sensitivity and specificity were the values yielding maximum sums from the ROC curves. P < 0.05 was considered statistically significant.

RESULTS

2.0% of participants were characterised by MetS, male and female shared the same prevalence of MetS (P > 0.05) (**Table 1**). The age, FPG, TG and LAP between male and female subjects were similar (P > 0.05). The levels of BMI, WC, SBP (systolic blood pressure) and DBP (diastolic blood pressure) were all significantly higher in male subjects (P < 0.05), while the levels of HDL-C and VAI were significantly lower in male subjects (P < 0.05). VAI showed a strong positive correlation with WC, DBP and TG and a negative correlation with HDL-C (P < 0.05). LAP showed a strong positive correlation with WC, SBP, DBP and TG and a negative correlation with HDL-C (P < 0.05) (**Table 2**).

In the male subjects, LAP had the highest AUC value (AUC = 0.963), followed by VAI (AUC = 0.937). LAP had a Youden's index of 0.85, with an optimal cut-off of 20.1. VAI had a Youden's index of 0.79, with an optimal cut-off of 1.96 (**Table 3**). In the female subjects, LAP had the highest AUC value (AUC = 0.931), followed by VAI (AUC = 0.861). LAP had a Youden's index of 0.75, with an optimal cut-off of 13.7. VAI had a Youden's index of 0.64, with an optimal cut-off of 1.34 (**Table 3**).

DISCUSSION

The outcomes of this study showed that the performance of LAP and VAI were similar, LAP may be more valuable for MetS in young adults.

Recently, MetS is considered as central obesity. BMI and WC are the main manifestations of MetS, but the sensitivity and specificity of diagnosis of MetS are insufficient (22). VAI is an

| TABLE 1 General characteristics of participants. | | | | | | | |
|--|------------------|--------------------|-------|-------|--|--|--|
| Variables | Males (n=235) | Females (n=213) | t | Р | | | |
| Age (year) | 19.3 ± 0.8 | 19.3 ± 0.8 | 0.131 | 0.896 | | | |
| BMI (kg/m ²) | 24.6 ± 4.3 | 23.6 ± 4.1 | 2.381 | 0.018 | | | |
| WC (cm) | 78.9 ± 11.8 | 70.1 ± 9.6 | 8.720 | 0.000 | | | |
| SBP (mmHg) | 116.1 ± 10.6 | 106.6 ± 10.1 | 9.688 | 0.000 | | | |
| DBP (mmHg) | 77.2 ± 9.1 | 71.5 ± 8.0 | 6.930 | 0.000 | | | |
| FPG (mmol/L) | 4.35 ± 0.45 | 4.30 ± 0.40 | 1.271 | 0.204 | | | |
| TG (mmol/L) | 0.74 ± 0.39 | 0.74 ± 0.26 | 0.003 | 0.998 | | | |
| HDL-C (mmol/L) | 1.31 ± 0.21 | 1.46 ± 0.23 | 6.785 | 0.000 | | | |
| VAI | 0.70 ± 0.59 | 0.86 ± 0.41 | 3.166 | 0.002 | | | |
| LAP | 11.4 ± 14.3 | 9.6 ± 9.2 | 1.597 | 0.111 | | | |

BMI, body mass index; WC, waist circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure; FPG, fasting plasma glucose; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; VAI, visceral adiposity index; LAP, lipid accumulation product.

| Variables | V | AI | LÆ | AP |
|-----------|--------|-------|--------|-------|
| | r | Р | r | Р |
| WC | 0.257 | 0.000 | 0.753 | 0.000 |
| SBP | 0.089 | 0.060 | 0.277 | 0.000 |
| DBP | 0.104 | 0.027 | 0.278 | 0.000 |
| FPG | 0.044 | 0.357 | 0.092 | 0.051 |
| TG | 0.932 | 0.000 | 0.716 | 0.000 |
| HDL-C | -0.448 | 0.000 | -0.347 | 0.000 |

TABLE 2 | Relationship between VAI, LAP and metabolic syndrome.

VAI, visceral adiposity index; LAP, lipid accumulation product; WC, waist circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure; FPG, fasting plasma glucose; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol.

| Variables | Cut-off | Sensitivity | Specificity | Youden's index | AUC (95%CI) | Р | P * |
|-----------|---------|-------------|-------------|----------------|--------------------|-------|------------|
| Males | | | | | | | |
| VAI | 1.96 | 80.0 | 99.5 | 0.79 | 0.937(0.826~1.000) | 0.001 | |
| LAP | 20.1 | 100.0 | 85.2 | 0.85 | 0.963(0.912~1.000) | 0.000 | 0.678 |
| Females | | | | | | | |
| VAI | 1.34 | 75.0 | 89.4 | 0.64 | 0.861(0.689~1.000) | 0.013 | |
| LAP | 13.7 | 100.0 | 75.5 | 0.75 | 0.931(0.829~1.000) | 0.003 | 0.493 |

AUC, area under curve; CI, confidence interval; VAI, visceral adiposity index; LAP, lipid accumulation product. *Compared with VAI.

important index reflecting the distribution of body fat, and the content of visceral fat is closely related to Mets (23). VAI has a certain effect in the diagnosis of MetS (24). The evaluation of visceral adipose tissue has limited availability due to expensive cost and radiation exposure. As the most accurate surrogate marker of visceral adiposity, WC may not be appropriate for identifying MetS (25, 26). However, LAP, as an accurate index for identifying adults at cardiovascular risk (19), is an index based on a combination of WC and TG. In our study, the results showed that LAP was closely related to the components of MetS. These results emphasise the clinical importance of assessing LAP in young adults to identify subjects at high cardiovascular risk.

VAI is an index estimated by anthropometricand metabolic parameters. Among elderly, VAI showed the lowest discriminatory power for MetS (12). Among Chinese rural adults, the VAI AUC for the screening of MetS was less than that of LAP in both men and women (27). However, VAI is not superior to LAP in our study which was consistent with previous results.

Limitations

On the one hand, LAP was derived from studies of white, non-Hispanic black and Mexican American subjects, but VAI was derived from Caucasian populations (18, 19). Their suitability for other populations needs to be further investigated. On the other hand, the incidence rate of MetS in this study was low, which may be related to the limited sample size.

REFERENCES

 Ciresi A, Radellini S, Guarnotta V, Giordano C. The Visceral Adiposity Index Is Associated With Insulin Sensitivity and IGF-I Levels in Adults With Growth Hormone Deficiency. *Endocrine* (2017) 56(3):579–88. doi: 10.1007/s12020-016-1076-5 In summary, two novel obesity indicators were demonstrated to be effective indicators for the screening of MetS in young adults, with LAP being the simpler of the two.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by The First Hospital of Qinhuangdao. The patients/ participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

XL, CPM conceived of the study, and FY and RW participated in its design and coordination and QL, NL and CMM helped to draft the manuscript. All authors contributed to the article and approved the submitted version.

- Gu D, Ding Y, Zhao Y, Qu Q. Visceral Adiposity Index Was a Useful Predictor of Prediabetes. *Exp Clin Endocrinol Diabetes* (2018) 126(10):596– 603. doi: 10.1055/s-0043-120440
- 3. Wu J, Gong L, Li Q, Hu J, Zhang S, Wang Y, et al. A Novel Visceral Adiposity Index for Prediction of Type 2 Diabetes and Pre-Diabetes in Chinese Adults:

A 5-Year Prospective Study. *Sci Rep* (2017) 7(1):13784. doi: 10.1038/s41598-017-14251-w

- Gu D, Ding Y, Zhao Y, Miao S, Qu Q. Positively Increased Visceral Adiposity Index in Hyperuricemia Free of Metabolic Syndrome. *Lipids Health Dis* (2018) 17(1):101. doi: 10.1186/s12944-018-0761-1
- Xu C, Ma Z, Wang Y, Liu X, Tao L, Zheng D, et al. Visceral Adiposity Index as a Predictor of NAFLD: A Prospective Study With 4-Year Follow-Up. *Liver Int* (2018) 38(12):2294–300. doi: 10.1111/liv.13941
- Bolat MS, Ozbek ML, Şahin B, Yılmaz M, Kocamanoglu F, Buyukalpelli R, et al. Impact of High Visceral Adiposity Index Associated With Metabolic Syndrome on Erectile Function in Sexually Active Men: Results of a Cross-Sectional Study. Int J Clin Pract (2021) 75(6):e14111. doi: 10.1111/ijcp.14111
- Bolat MS, Kocamanoglu F, Ozbek ML, Buyukalpelli R, Asci R. Can High Visceral Adiposity Index Be a Risk Factor for Sexual Dysfunction in Sexually Active Men? J Sex Med (2020) 17(10):1926–33. doi: 10.1016/j.jsxm. 2020.06.014
- Taverna MJ, Martínez-Larrad MT, Frechtel GD, Serrano-Ríos M. Lipid Accumulation Product: A Powerful Marker of Metabolic Syndrome in Healthy Population. *Eur J Endocrinol* (2011) 164(4):559–67. doi: 10.1530/ EJE-10-1039
- Chiang JK, Koo M. Lipid Accumulation Product: A Simple and Accurate Index for Predicting Metabolic Syndrome in Taiwanese People Aged 50 and Over. BMC Cardiovasc Disord (2012) 12:78. doi: 10.1186/1471-2261-12-78
- Motamed N, Razmjou S, Hemmasi G, Maadi M, Zamani F. Lipid Accumulation Product and Metabolic Syndrome: A Population-Based Study in Northern Iran, Amol. J Endocrinol Invest (2016) 39(4):375–82. doi: 10.1007/s40618-015-0369-5
- Schuster J, Vogel P, Eckhardt C, Morelo SD. Applicability of the Visceral Adiposity Index (VAI) in Predicting Components of Metabolic Syndrome in Young Adults. *Nutr Hosp* (2014) 30(4):806–12. doi: 10.3305/nh. 2014.30.4.7644
- de Oliveira CC, Roriz AK, Ramos LB, Gomes Neto M. Indicators of Adiposity Predictors of Metabolic Syndrome in the Elderly. *Ann Nutr Metab* (2017) 70 (1):9–15. doi: 10.1159/000455333
- Goldani H, Adami FS, Antunes MT, Rosa LH, Fassina P, Quevedo Grave MT, et al. Applicatility OF the VISCERAL Adiposity INDEX (Vai) IN the PREDICTION of THE Components OF the METABOLIC Syndrome IN Elderly. *Nutr Hosp* (2015) 32(4):1609–15. doi: 10.3305/nh.2015.32.4.9589
- Xiang S, Hua F, Chen L, Tang Y, Jiang X, Liu Z. Lipid Accumulation Product Is Related to Metabolic Syndrome in Women With Polycystic Ovary Syndrome. *Exp Clin Endocrinol Diabetes* (2013) 121(2):115–8. doi: 10.1055/ s-0032-1333261
- Macut D, Božić Antić I, Bjekić-Macut J, Panidis D, Tziomalos K, Vojnović Milutinović D, et al. Lipid Accumulation Product Is Associated With Metabolic Syndrome in Women With Polycystic Ovary Syndrome. *Hormones (Athens)* (2016) 15(1):35–44. doi: 10.14310/horm.2002.1592
- Techatraisak K, Wongmeerit K, Dangrat C, Wongwananuruk T, Indhavivadhana S. Measures of Body Adiposity and Visceral Adiposity Index as Predictors of Metabolic Syndrome Among Thai Women With PCOS. *Gynecol Endocrinol* (2016) 32(4):276–80. doi: 10.3109/09513590. 2015.1112785
- 17. Chan L, Xue H, Xiaoya Z, Jiajia X, Wei R, Linman L, et al. Lipid Accumulation Product: A Simple and Accurate Index for Predicting Metabolic Syndrome in

Patients With Adult Growth Hormone Deficiency. *Exp Clin Endocrinol Diabetes* (2016) 124(4):220-4. doi: 10.1055/s-0035-1569402

- Amato MC, Giordano C, Galia M, Criscimanna A, Vitabile S, Midiri M, et al. Visceral Adiposity Index: A Reliable Indicator of Visceral Fat Function Associated With Cardiometabolic Risk. *Diabetes Care* (2010) 33(4):920–2. doi: 10.2337/dc09-1825
- Kahn HS. The "Lipid Accumulation Product" Performs Better Than the Body Mass Index for Recognizing Cardiovascular Risk: A Population-Based Comparison. BMC Cardiovasc Disord (2005) 5:26. doi: 10.1186/1471-2261-5-26
- 20. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the Metabolic Syndrome: A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. *Circulation* (2009) 120 (16):1640–5. doi: 10.1161/CIRCULATIONAHA.109.192644
- Zou KH, O'Malley AJ, Mauri L. Receiver-Operating Characteristic Analysis for Evaluating Diagnostic Tests and Predictive Models. *Circulation* (2007) 115 (5):654–7. doi: 10.1161/CIRCULATIONAHA.105.594929
- Hu X, Xu G. Does Anaesthesia Cause Postoperative Cognitive Decline. Med PRIN Pract (2016) 25(5):497. doi: 10.1159/000446541
- 23. Cao YH, Chi P, Zhao YX, Dong XC. Effect of Bispectral Index-Guided Anesthesia on Consumption of Anesthetics and Early Postoperative Cognitive Dysfunction After Liver Transplantation: An Observational Study. *Medicine* (2017) 96(35):e7966. doi: 10.1097/MD.000000000007966
- Emik U, Unal Y, Arslan M, Demirel CB. The Effects of Memantine on Recovery, Cognitive Functions, and Pain After Propofol Anesthesia. *Braz J Anesthesiol* (2016) 66(5):485–91. doi: 10.1016/j.bjane.2015.03.002
- 25. Nazare JA, Smith J, Borel AL, Aschner P, Barter P, Van Gaal L, et al. Usefulness of Measuring Both Body Mass Index and Waist Circumference for the Estimation of Visceral Adiposity and Related Cardiometabolic Risk Profile (From the INSPIRE Me IAA Study). Am J Cardiol (2015) 115(3):307– 15. doi: 10.1016/j.amjcard.2014.10.039
- 26. Lim JS, Choi YJ, Kim SK, Huh BW, Lee EJ, Huh KB. Optimal Waist Circumference Cutoff Value Based on Insulin Resistance and Visceral Obesity in Koreans With Type 2 Diabetes. *Diabetes Metab J* (2015) 39 (3):253–63. doi: 10.4093/dmj.2015.39.3.253. doi: 10.1016/j.tem.2011.12.005.
- Guo SX, Zhang XH, Zhang JY, He J, Yan YZ, Ma JL, et al. Visceral Adiposity and Anthropometric Indicators as Screening Tools of Metabolic Syndrome Among Low Income Rural Adults in Xinjiang. *Sci Rep* (2016) 6:36091. doi: 10.1038/srep36091

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Liu, Ma, Yin, Wang, Lu, Lu and Ma. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.